Matuzumab
- Generic Name
- Matuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339186-68-4
- Unique Ingredient Identifier
- MG4M3QB242
- Background
Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.
- Indication
Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 72
- Registration Number
- NCT00215644
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 150
- Registration Number
- NCT00111839
- Locations
- 🇺🇸
University of Southern California/Norris Cancer Center, Los Angeles, California, United States
🇺🇸Peachtree Hematology and Oncology, Atlanta, Georgia, United States
🇺🇸Georgia Cancer Specialists, Tucker, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.